FindTrial
Sign In

A Machine Learning-Based Study for Predicting Delayed Excretion Risk of High-Dose Methotrexate in Adult Patients with Hematologic Malignancies

A Machine Learning-Based Study for Predicting Delayed Excretion Risk of High-Dose Methotrexate in Adult Patients with Hematologic Malignancies

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121879
Enrollment
Unknown
Registered
2026-04-07
Start date
2026-04-07
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Malignancies

Interventions

Observation group:None

Sponsors

Nanjing Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with hematologic malignancies, including but not limited to primary central nervous system diffuse large B-cell lymphoma, Burkitt lymphoma, high-grade B-cell lymphoma, and T/B lymphoblastic lymphoma/leukemia. 2. Aged >= 18 years. 3. Received chemotherapy regimens containing high-dose methotrexate (HD-MTX, >= 500 mg/m^2) during hospitalization. 4. Underwent plasma methotrexate concentration measurements at 24 hours, 48 hours, and/or 72 hours post-methotrexate administration during hospitalization. 5. Received high-dose methotrexate treatment between 2018 and 2025 (applicable only for retrospective data selection).

Exclusion criteria

Exclusion criteria: The patient declines to participate in the study.

Design outcomes

Primary

MeasureTime frame
Plasma Concentration of Methotrexate;—

Secondary

MeasureTime frame
Gender, age, weight;—

Countries

China

Contacts

Public ContactLv Chenglan

Nanjing Drum Tower Hospital

lclqusi13932006@163.com+86 25 8310 6666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026